Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
Publication
, Journal Article
Morse, M; Gabitzsch, E; Balint, JP; Xu, Y; Lyerly, HK; Jones, F
Published in: Journal for immunotherapy of cancer
January 2013
Duke Scholars
Published In
Journal for immunotherapy of cancer
DOI
EISSN
2051-1426
ISSN
2051-1426
Publication Date
January 2013
Volume
1
Issue
Suppl 1
Start / End Page
P129 / P129
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Morse, M., Gabitzsch, E., Balint, J. P., Xu, Y., Lyerly, H. K., & Jones, F. (2013). Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Journal for Immunotherapy of Cancer, 1(Suppl 1), P129–P129. https://doi.org/10.1186/2051-1426-1-s1-p129
Morse, Michael, Elizabeth Gabitzsch, Joseph P. Balint, Younong Xu, H. K. Lyerly, and Frank Jones. “Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Journal for Immunotherapy of Cancer 1, no. Suppl 1 (January 2013): P129–P129. https://doi.org/10.1186/2051-1426-1-s1-p129.
Morse M, Gabitzsch E, Balint JP, Xu Y, Lyerly HK, Jones F. Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Journal for immunotherapy of cancer. 2013 Jan;1(Suppl 1):P129–P129.
Morse, Michael, et al. “Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Journal for Immunotherapy of Cancer, vol. 1, no. Suppl 1, Jan. 2013, pp. P129–P129. Epmc, doi:10.1186/2051-1426-1-s1-p129.
Morse M, Gabitzsch E, Balint JP, Xu Y, Lyerly HK, Jones F. Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Journal for immunotherapy of cancer. 2013 Jan;1(Suppl 1):P129–P129.
Published In
Journal for immunotherapy of cancer
DOI
EISSN
2051-1426
ISSN
2051-1426
Publication Date
January 2013
Volume
1
Issue
Suppl 1
Start / End Page
P129 / P129
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology